TIDMPRTC
RNS Number : 1066A
PureTech Health PLC
27 May 2021
27 May 2021
PureTech Health plc
Results of Annual General Meeting
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC,
LSE: PRTC) ("PureTech Health" or the "Company") was held at 11 a.m.
EDT/4 p.m. BST on Thursday, May 27, 2021. All of the resolutions
proposed at the Annual General Meeting were duly passed by the
shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in
advance of the meeting, are set out below.
Resolutions For % Against % Withheld Total
votes
cast
001. To approve
the Company's
Annual Report
and Accounts for
year ended 31
December 2020 225,240,798 100.00% 10,921 0.00% 273,846 225,251,719
------------ -------- ----------- ------- ---------- ------------
002. To approve
the Directors'
Remuneration Report 200,319,991 89.74% 22,895,826 10.26% 2,309,748 223,215,817
------------ -------- ----------- ------- ---------- ------------
003. To approve
the Directors'
Remuneration Policy 187,285,809 83.90% 35,930,008 16.10% 2,309,748 223,215,817
------------ -------- ----------- ------- ---------- ------------
004. To elect
Dr. Raju Kucherlapati
as a director 222,659,203 98.73% 2,865,525 1.27% 837 225,524,728
------------ -------- ----------- ------- ---------- ------------
005. To elect
Dr. John LaMattina
as a director 218,438,727 96.86% 7,086,001 3.14% 837 225,524,728
------------ -------- ----------- ------- ---------- ------------
006. To elect
Ms. Kiran Mazumdar-Shaw
as a director 189,257,653 84.32% 35,193,037 15.68% 1,074,875 224,450,690
------------ -------- ----------- ------- ---------- ------------
007. To elect
Dame Marjorie
Scardino as a
director 222,228,072 98.54% 3,296,656 1.46% 837 225,524,728
------------ -------- ----------- ------- ---------- ------------
008. To elect
Mr. Christopher
Viehbacher as
a director 199,985,210 88.68% 25,539,518 11.32% 837 225,524,728
------------ -------- ----------- ------- ---------- ------------
009. To elect
Dr. Robert Langer
as a director 218,164,180 96.74% 7,360,548 3.26% 837 225,524,728
------------ -------- ----------- ------- ---------- ------------
010. To elect
Ms. Daphne Zohar
as a director 225,474,510 99.98% 50,218 0.02% 837 225,524,728
------------ -------- ----------- ------- ---------- ------------
011. To elect
Dr. Bharatt Chowrira
as a director 225,473,830 99.98% 50,898 0.02% 837 225,524,728
------------ -------- ----------- ------- ---------- ------------
012. To reappoint
KPMG LLP as Auditors
of the Company 225,291,096 99.90% 234,469 0.10% 0 225,525,565
------------ -------- ----------- ------- ---------- ------------
013. To authorize
the Audit Committee
to determine the
Auditors' remuneration 225,483,695 99.98% 41,870 0.02% 0 225,525,565
------------ -------- ----------- ------- ---------- ------------
014. To authorize
the allotment
of shares 221,538,872 98.23% 3,986,693 1.77% 0 225,525,565
------------ -------- ----------- ------- ---------- ------------
015. To disapply
pre-emption rights 225,102,915 99.81% 422,650 0.19% 0 225,525,565
------------ -------- ----------- ------- ---------- ------------
016. To further
disapply pre-emption
rights for acquisitions
and specified
capital investments. 215,316,258 95.47% 10,209,307 4.53% 0 225,525,565
------------ -------- ----------- ------- ---------- ------------
017. To authorize
market purchase
of own shares 225,235,005 99.89% 258,692 0.11% 31,868 225,493,697
------------ -------- ----------- ------- ---------- ------------
018. To authorize
general meetings
to be called on
not less than
14 clear days'
notice 222,063,258 98.46% 3,462,307 1.54% 0 225,525,565
------------ -------- ----------- ------- ---------- ------------
Notes:
(1) A vote "Withheld" is not a vote in law and is not counted in
the calculation of the votes "For" or "Against" a resolution.
(2) As at May 27, 2021 the number of issued shares in the
Company was 286,018,538 ordinary shares, which was the total number
of shares entitling the holders to attend and vote for or against
all the resolutions at the AGM. In accordance with the Company's
Articles of Association, on a poll every member present in person
or by proxy has one vote for every share held.
(3) The full text of the resolutions may be found in the Notice
of the Annual General Meeting, copies of which are available on
both the Company's website
https://investors.puretechhealth.com/financials-filings/reports and
on the National Storage Mechanism.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech ' s
Founded Entities, is comprised of 26 therapeutics and therapeutic
candidates, including two that have received FDA clearance and
European marketing authorization, as of the date of PureTech's most
recently filed Annual Report on Form 20-F. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company ' s unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited to
, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors
Allison Mead Talbot
+1 617 651 3156
amt@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGDKOBKOBKDFPB
(END) Dow Jones Newswires
May 27, 2021 13:16 ET (17:16 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024